Impetigo: Diagnosis and Treatment
Evening snacking from high-fat foods decreased by 35%
Full disclaimer 1.Retatrutide (LY3437943) is a first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors, developed by Eli Lilly 2.Phase 2 trials demonstrated up to 24.2% body weight loss at 48 weeksthe highest weight loss ever reported in a Phase 2 obesity trial 3.Triple mechanism activates multiple metabolic pathways: appetite suppression (GLP-1), improved insulin sensitivity (GIP), and increased energy expenditure (glucagon) 4.Currently in Phase 3 TRIUMPH trials for weight management, type 2 diabetes, NASH, and osteoarthritis
Gastrointestinal side effects are the most commonly reported adverse events associated with retatrutide in clinical trials, consistent with the broader class of incretin-based therapies
NO REPRESENTATIONS : The Company makes no representations at all about the information provided on the Website
Suspected adverse reactions should be reported to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app
